In diabetes, endothelial dysfunction leads to vascular complications that negatively impact on patient outcome. Endothelial dysfunction may be mediated by hyperglycemia-induced oxidative stress, protein kinase C-β (PKC-β) activation and endoplasmic reticulum (ER) stress. As these events are antagonized by glucagon-like peptide-1 (GLP-1), a therapeutic strategy able to increase GLP-1 levels may prevent endothelial impairment, providing a clinical benefit to diabetic patients.
Introduction
Glucagon-like peptide-1 (GLP-1) is a hormone released by the intestinal L cells in response to food intake. This mediator is rapidly degraded by dipeptidyl peptidase-4 (DPP-4), a ubiquitous transmembrane glycoprotein that cleaves N-terminal dipeptides from a variety of substrates. As a result, the half-life of circulating GLP-1 is 1-2 minutes. Besides its key role in the regulation of insulin secretion and glucose homeostasis [1] , GLP-1 is also emerging as an important player in the protection of kidney and cardiovascular system [2] [3] [4] . Moreover, GLP-1 improves endothelial function, and this is particularly important in the context of diabetes, in which hyperglycemia and oxidative stress lead to endothelial dysfunction, ultimately resulting in vascular complications. Evidence suggests that in diabetes, due to continuous exposure to high levels of glucose, the protective action of GLP-1 is significantly decreased [5, 6] . Two mechanisms have been proposed to explain this phenomenon: i) hyperglycemia-induced activation of protein kinase C beta (PKC-β), which is able to reduce the expression of GLP-1 receptors [6] , and ii) hyperglycemia-generated oxidative stress [5] . Indeed, a recent in vivo study showed that the administration of the antioxidant vitamin C was able to improve both GLP-1 action and hyperglycemia control [5] . On the other hand, in endothelial cells, GLP-1 may counteract the high glucose-induced endoplasmic reticulum (ER) stress [7] , which has been implicated in type 2 diabetes (T2D) and endothelial dysfunction [8, 9] . Under ER stress, the unfolded protein response (UPR) is activated in order to restore normal ER homeostasis [8] . UPR acts by promoting the inhibition of protein synthesis, the degradation of misfolded proteins and the production of molecular chaperones involved in protein folding [8] . A key player of UPR is immunoglobulin protein (BIP), a chaperone that usually maintains in the inactive form the three transmembrane sensors of ER stress: protein kinase RNA-like ER kinase (PERK), inositol requiring enzyme 1α (IRE-1 α) and activating transcription factor-6. Under ER stress, BIP dissociates from the sensors, that can thus induce the expression of different target genes, and retranslocates misfolded proteins [8] . In case of prolonged ER stress, PERK signaling triggers apoptosis [10] . In this context, one major event is the induction of CCAAT-enhancerbinding protein homologous protein (CHOP), that, in turn, modulates the expression of several BCL-2 family members [10, 11] .
In the past decade, therapeutic strategies aimed at increasing levels of circulating GLP-1 by inhibiting DPP-4 have been developed and shown to be effective in T2D [12, 13] . Vildagliptin is a DPP-4 inhibitor that has displayed better antioxidant properties than other compounds in its class [12] [13] [14] , significantly lowering oxidative stress-related markers. Still, to date, available data are poor.
The aim of this study was to investigate the anti-oxidant properties of vildagliptin, compared to another DDP-4 inhibitor, sitagliptin, on human umbilical vein endothelial cells (HUVECs) exposed to high levels of glucose. Moreover, the effects of both inhibitors on PKC-β activation and ER/UPR stress markers were evaluated.
Materials and Methods

Cell culture and experimental design
HUVECs were purchased from Lonza (Lonza Bioresearch LBS, Basel, Switzerland) and cultured with EGM™-2 Bulletkit™ (Lonza) supplemented with human epidermal growth factor (hEGF), hydrocortisone, human recombinant fibroblast growth factor-beta (hFGF-b), heparin, 2% fetal bovine serum (FBS), and gentamicin/ amphotericin-B (GA), at 37°C in a humidified atmosphere with 5% CO 2 . Cells were used at passage 4 to avoid age-dependent cellular modifications, and plated in duplicate at a density of 2 × 10 5 in 6-well plates for total RNA and protein extraction, and at 1 × 10 4 in 96-well plates for reactive oxygen species (ROS) measurement. Briefly, after seeding, HUVECs were allowed to attach overnight and 1 day later were exposed to either normal (5 mM) or high (25 mM) glucose concentrations (NG and HG, respectively) and cultured for a further 21 days. Vildagliptin (5 nM), sitagliptin (5 nM) (Sigma-Aldrich, St Louis, MO, USA) or GLP-1 (50 nM) (Sigma-Aldrich) were added to cells 1 hour before cell harvesting for the subsequent analyses.
Measurement of ROS
The fluorescent probe 2′,7′-dichlorofluorescein diacetate (H2DCFDA, Invitrogen, Carlsbad, California, USA) was used to measure the intracellular generation of ROS, following the manufactur's instructions. After a 1 hr-incubation with the indicated drugs, cells were stained with 20 µM H2DCFDA for 30 min at 37°C. Fluorescence intensity of H2DCFDA was kinetically measured at an excitation and emission wavelength of 485 nm and 530 nm, respectively, using a fluorescent microplate reader (Synergy HT, BioTek Instruments, Inc., Winooski, Vermont, USA).
RNA isolation and qRT-PCR
Total RNA was isolated from HUVECs using a total RNA isolation kit (Norgen Biotek Corp, Thorold, Ontario, Canada) following the manufacturer's instructions. First-strand cDNA was prepared using 1-2 µg of total RNA, the Superscript III RT kit and random hexamer primers (Invitrogen, Carlsbad, CA, USA) in a total volume of 25 µl according to the manufacturer's instructions. Reverse transcription was carried out for 90 min at 50°C followed by 10 min at 55°C. qRT-PCR was performed on a QuantStudio 6 flex (Applied Biosystem) detection system using SybrGreen reagents (Takara Bio Company, Clontech, Mountain View, CA, USA) and TaqMan® Gene Expression Master Mix (Thermo Fisher Scientific, Waltham, MA, USA).
The expression of the following markers was evaluated (primers and conditions are listed in Table 1 ; thioredoxin-interacting protein (TXNIP) and PKC-β (oxidative stress), BAX and BCL-2 (apoptosis), and BIP, CHOP and IRE-1α (ER/UPR stress). Table 1 : Primers used to assess the transcript levels of the indicated genes by quantitative-Real Time-PCR, in HUVECs either untreated or treated with vildagliptin or sitagliptin upon different glucose conditions.
Protein analysis
For western blot analysis, HUVECs were lysed in RIPA buffer (Sigma-Aldrich) with 10% protease and 1% phosphatase inhibitors (Sigma-Aldrich). Protein content was determined using the Bradford assay buffer (Sigma-Aldrich), and 50 µg of lysates were separated by electrophoresis using 4-12% PAGE gels (Lonza) and transferred onto a PVDF membrane (Perkin Elmer, Waltham, MA, USA). After blocking with 5% non-fat dried milk or 5% bovine serum albumin, membranes were incubated with primary antibodies 1:500 anti-GLP-1 receptor (GLP-1R, Abcam, Cambridge, UK) and 1:1,000 anti-β-actin (Sigma-Aldrich, St Louis, MO, USA) overnight at 4°C. After incubation with the appropriate secondary horseradish peroxidase-conjugated IgG antibodies (GE Healthcare Europe GmbH, Milan, Italy) at a 1:3,000 dilution for 1 h at room temperature, blots were visualized by LI-COR ECL Reagent and C-DiGit Blot scanner (LI-COR Biosciences). Proteins were quantitated by the Image Studio software (www.licor.com). β-actin served as the loading control.
Statistical analysis
All experiments were repeated three times. Numerical data were expressed as mean ± standard error of the mean (SEM). Statistical analysis was performed using the one-way analysis of variance (ANOVA) with appropriate post-hoc multi-comparison tests (Tukey's) to compare the effects of vildagliptin, sitagliptin and GLP-1. A P-value of <0.05 was considered statistically significant.
Results
Effect of DDP-4 inhibitors on hyperglycemia-induced ROS generation
ROS generation was assessed by a fluorometric assay in HUVECs cultured for 21 days under NG or HG conditions and then exposed for 1h to vildagliptin, sitagliptin or GLP-1. As shown in Figure 1 , compared to NG, HG significantly increased the production of ROS in untreated cells of approximately 3 fold (p<0.001). However, following treatment, the content of ROS significantly decreased under HG but not under NG, and the reduction was slightly lower following vildagliptin (P<0.05) compared to sitagliptin and GLP-1 (P<0.01).
Effect of DDP-4 inhibitors on hyperglycemia-induced TXNIP up-regulation
Compared to NG, HG significantly up-regulated by (approximately 3-fold) TXNIP transcript in untreated HUVECs (P<0.001) ( Figure 2 ). Yet, this increase was partly reversed by 1h-exposure to vildagliptin, sitagliptin and GLP-1, but the significance was reached only upon vildagliptin and GLP-1 (P<0.05). Moreover, the levels of TXNIP mRNA observed in vildagliptin-and sitagliptin-treated cells remained significantly higher than those in the corresponding conditions upon NG (P<0.05). No change was observed following any treatment under NG conditions. 
Effect of DDP-4 inhibitors on hyperglycemia-induced deregulation of apoptosis-related markers
We next investigated the levels of the apoptotic markers BAX (proapoptotic) and BCL-2 (anti-apoptotic) by qRT-PCR ( Figure 3 ). In untreated cells, compared to NG, HG led to significant BAX upregulation (p<0.01) ( Figure 3A ), but no BCL-2 change ( Figure 3B ). Under HG conditions, treatment with vildagliptin, sitagliptin and GLP-1 significantly decreased BAX transcript levels (p<0.05), restoring similar levels observed upon NG ( Figure 3A) . Conversely, exposure to any drug upon HG led to significant BCL-2 up-regulation (p<0.001 upon vildagliptin; p<0.01 upon sitagliptin and GLP-1) ( Figure 3B ). 
Effect of DDP-4 inhibitors on hyperglycemia-induced PKC-β transcript up-regulation
(p<0.01, p<0.01 and p<0.001, respectively), and all agents restored levels comparable to those found upon NG. In contrast, under NG conditions, none of the drugs exerted any effect on PKC-β expression. 
Effect of DDP-4 inhibitors on hyperglycemia-induced ER/UPR gene expression
The transcript level of the well-established markers of ER stress BIP, CHOP and IRE-1α was assessed. Prolonged exposure to HG, compared to NG, significantly increased their levels in untreated cells, and did so to a similar extent (p<0.001 in each case) ( Figure 5 ). However, treatment with vildagliptin, sitagliptin and GLP-1 led to a significant reduction of all markers down to levels comparable to those observed upon NG (p<0.001 in all cases except for sitagliptin and GLP-1 on BIP levels: p<0.01) ( Figure 5 ). Under NG conditions, no treatment exerted any effect on BIP, CHOP and IRE-1α expression.
Effect of DDP-4 inhibitors on hyperglycemia-induced downregulation of GLP-1 receptor
The expression of GLP-1R was assessed by Western blotting. A significant down-regulation was observed in untreated cells exposed to HG compared to those grown with NG (by approximately 50%, p<0.05) ( Figure 6 ). Compared to untreated cells, each drug was able to significantly increase the expression of GLP-1R in HG (p<0.01), restoring levels similar to those observed under NG. Under NG conditions, no significant difference occurred upon any drug compared to untreated cells. 
Discussion
DPP-4 inhibitors are effective drugs for the treatment of T2DM [12, 13] . They act by increasing the levels of biologically intact GLP-1, which, in turn, enhances glucose metabolism through the upregulation of insulin secretion and the suppression of glucagon release. Moreover, GLP-1 protects endothelial cells from hyperglycemiainduced dysfunction that may be caused by oxidative stress. Vildagliptin is a DPP-4 inhibitor that displays more prolonged DPP-4 enzyme inhibition (acting as a substrate-blocker) compared to sitagliptin (acting, conversely, as a competitive inhibitor), thereby resulting in higher GLP-1 plasma levels upon the former compared to the latter [14] [15] [16] .
In the present study, we tested the effects of both DDP-4 inhibitors on different hyperglycemia-induced events in HUVECs. Results showed that vildagliptin, as well as sitagliptin, can reverse, at least in part, the effects triggered by the prolonged exposure to HG. Indeed, they were able to restore, for most of the markers examined, levels down to those observed under NG. We previously tested the effects of another DDP-4 inhibitor, teneligliptin, on these markers, and compared its activity to that of sitagliptin [7] . Results were similar to the findings reported here, further confirming the protective effect exerted by DDP-4 inhibition on endothelial cells, at least for the markers taken into account. Although we did not assess the activity of DDP-4 following treatment with vildagliptin and sitagliptin, we used 50 nM GLP-1 as a positive control throughout the study, and observed comparable effects by the three agents. In particular, they affected the levels of the GLP-1R protein, a mediator of most of the main effects of GLP-1, to a similar extent upon both NG and HG, suggesting that these two inhibitors actually act by increasing the levels of endogenous GLP-1.
It is well established that, upon continuous exposure to HG, PKC-β activation occurs, that triggers oxidative stress [17] . This, in turn, leads to increased apoptosis and reduced protection of endothelial cells by GLP-1, leading to dysfunction and finally to diabetic vascular complications [7, 18, 19] . In our experimental model, compared to NG conditions, exposure to HG actually increased the content of ROS and the expression of the oxidative stress marker TXNIP, of PKC-β, of ER/UPR stress markers BIP, CHOP and IRE-1α and of the proapoptotic BAX. Conversely, it decreased the expression of GLP-1R, while exerting no effect on the expression of BCL-2. 1h-treatment with GLP-1 was able to significantly counteract these events, and the exposure to vildagliptin and sitagliptin, which increase the levels of endogenous GLP-1 by inhibiting DDP-4, led to similar results, pointing toward their antioxidant capacity, confirming our previous findings [7] . Moreover, our findings show that vildagliptin and sitagliptin may counteract the overall pro-apoptotic effect induced by HG, stimulating BCL-2 and reducing BAX expression at the same time. Notably, it has been reported that, upon induction of prolonged ER stress-mediated apoptosis, CHOP is up-regulated and modulates the levels of different mediators of apoptosis, such as Bcl-2 [11] and Bax [20] .
It has been proposed that GLP-1 could restore HG-induced ER stress in endothelial cells. Impairment of ER function triggers ER stress, leading to UPR activation (through BIP, CHOP and IRE-1α), which causes inhibition of protein synthesis, protein refolding, and clearance of misfolded proteins. Although each UPR pathway activates different target genes, the overall result is that the cell can counteract the endogenous stress of unfolded proteins by shutting off the synthesis of new proteins [16] . It is well known that HG induces the expression of ER stress-related genes, and this was confirmed also in our model. Notably, vildagliptin and sitagliptin had the capacity to down-regulate the expression level of BIP, CHOP and IRE-1α in HUVECs cultured under HG, thus reversing HG-induced ER stress. Recently, it has been shown that the expression of GLP-1R was reduced in HUVECs exposed to HG, but could be partially restored by a PKC-β-specific inhibitor [7] . Interestingly, upon HG, we observed an increase of PKCβ transcript and a decrease of GLP-1R protein level.
This study does present with some limitations. First, following treatment with vildagliptin and sitagliptin, we evaluated apoptosis induction by BAX and BCL2 transcript levels, but not HUVEC viability and proliferation. We focused on apoptosis as it is a wellestablished effect triggered by hyperglycemia [21] . Accordingly, it has been previously shown that HG-induced apoptosis in HUVECs is accompanied by increased Bax/Bcl 2 ratio [21] [22] [23] , that can be reverted, at least partly, by treatment with DDP-4 inhibitors [7] . Second, we did not investigate the possible effects of DDP-4 inhibitors on nitric oxide synthase (eNOS) expression and activity, as it was well beyond the scope of this study and in vitro and in vivo studies have already provided evidence linking GLP-1, DDP-4 inhibitors, eNOS and endothelial function [24] [25] [26] [27] [28] . Impairment of eNOS is recognized as the major mechanism leading to macrovascular complications in T2DM. Notably, this enzyme has been implicated in GLP-1-induced vasorelaxation in vivo [24] and, in HUVECs, GLP-1 increased eNOS protein expression and activity through GLP-1R-dendent andindependent mechanisms [25] . In ischemic mice, vildagliptin has been recently shown to promote revascularization through eNOS activation [28] and sitagliptin enhanced the levels of circulating EPC and neovasculogenesis in an eNOS-dependent fashion [27] . These results warrant further investigations, also to better clarify the possible different cardiovascular effects of the different agents currently employed in the treatment of diabetic patients. Moreover, it is necessary to yield more definitive information on the protective and antioxidant capacity of DDP-4 inhibitors by focusing on the expression profile of different markers, as well as on the improvement of the assessment of the cellular redox state.
In conclusion, our findings provide evidence supporting the protective action of vildagliptin and sitagliptin against HG-induced processes on endothelial cells. Notably, their effects mimic those of GLP-1, which is known to play a key role in the maintenance of CV system homeostasis.
